Business Wire

Waters Introduces High Resolution Mass Spectrometry Products and Software to Accelerate Drug Development

Share

ASMS 2022 – Waters Corporation (NYSE:WAT) today unveiled new instruments, software and product enhancements to drive drug discovery and development at the American Society for Mass Spectrometry (ASMS) 2022 Annual Conference. The products include the new Xevo™ G3 quadrupole time-of-flight (QTof) mass spectrometer, CONFIRM Sequence - a new oligonucleotide sequencing confirmation app for the waters_connect™ software platform and an electrospray ionization source for the high-resolution Waters™ SELECT SERIES™ Multi-Reflecting Time of Flight (MRT) mass spectrometer.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005253/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The new Xevo G3 QTof system is a high-performance, benchtop mass spectrometer for characterizing and quantifying thermally-fragile molecules in applications such as biotherapeutics, forensics, metabolite identification, metabolomics and extractables and leachables. (Photo: Business Wire)

“Innovation in mass spectrometry progresses rapidly. Our product introductions at this year’s ASMS benefit scientists throughout the drug development cycle,” said Jon Pratt, Senior Vice President, Waters Corporation. “For researchers, this means enhanced capability to answer fundamental scientific questions. For the analytical scientist compiling analytical data for new drug filings, it means increased certainty and confidence in knowing precisely what’s in their samples and in what quantities.”

Waters Xevo G3 QTof – A Laboratory Workhorse

The new Xevo G3 QTof system is a high-performance, benchtop mass spectrometer for characterizing and quantifying molecules in applications such as biotherapeutics, forensics, metabolite identification, metabolomics and extractables and leachables. The Xevo G3 QTof system is up to 10X more sensitive than its class-leading predecessor at transmitting thermally fragile molecules and excels at measuring and characterizing denatured or native proteins, peptides and other biotherapeutics.

“Biopharmaceutical development and commercialization requires a deep understanding of product variation, their degradation pathways and the processes that make them,” said Dr. Andrew Mahan, Associate Director, Mass Spectrometry Group Leader, Cell Engineering and Early Development, Janssen. “The extended mass-to-charge ratio (m/z) range of the Xevo G3 QTof is going to be ideal for the analysis of multi-specifics and for native MS analyses.”

Waters engineered the Xevo G3 QTof system to reliably give scientists both reproducible and accurate qualitative and quantitative information about molecules in their samples whether in very small or very large amounts.

New Software App for Confirming Nucleic Acid Sequence of Biotherapeutics

The CONFIRM Sequence app on the waters_connect software platform helps scientists using a Waters LC-MS System to confirm the nucleic acid sequence of therapeutics and identify impurities that could compromise product safety and efficacy.

The CONFIRM Sequence app eliminates 50% of the time it takes for post-processing data review, accelerating characterization and development of nucleic acid therapeutics.iii

The new CONFIRM Sequence app is the first sequencing tool to integrate compliance-ready data acquisition, processing, and reporting - making it ideal for deployment in regulated development and Good Manufacturing Practice (GMP) labs.

Coupling UPLC™ to Waters MRT SELECT SERIES Research Mass Spectrometer with ESI Source for Fast Molecular Characterization

The Waters SELECT SERIES MRT System is now compatible with UPLC-MS with an available electrospray ionization (ESI) source. Coupling the high resolution MRT System with the ESI source enables scientists to accurately resolve and measure low (<200 ppb) concentrations of sample analytes at UPLC acquisition speeds for metabolomics, metabolite identification or peptide mapping applications.

The superior performance of the SELECT SERIES MRT allows scientists to get the highest quality mass spectrometry data and information faster than any commercial mass spectrometer on the market today, giving scientists a much clearer picture of the structure of their molecules at the isotope level iv.

Additional Resources

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE:WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, and food sciences for more than 60 years. With more than 7,800 employees worldwide, Waters operates directly in more than 35 countries, including 14 manufacturing facilities, and with products available in more than 100 countries.

Waters, Xevo, SELECT SERIES, UPLC and waters_connect are trademarks of Waters Corporation.

i Vs. the Waters Xevo G2-XS
ii For thermally-labile compounds
iii Internal estimate based on 30 minutes to review a single oligo sequence data set in CONFIRM Sequence compared to 90 minutes with ThermoFisher’s BioPharma Finder.
iv Waters SELECT SERIES MRT mass resolution >200k FWHM @ m/z 785 and independent of scan time; highest resolution achieved irrespective of scan rate

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Brian J. Murphy
PR Manager, Corporate Communications
Waters Corporation
brian_j_murphy@waters.com
+1 508-482-2614

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

PUMA Football Players and Athletes Nikita Parris, Ingrid Engen, Fridolina Rolfö and Sara Björk Gunnarsdottir Talk “She Moves Us” Ahead of Women’s Euro in England27.6.2022 19:40:00 CEST | Press release

Football players and PUMA Athletes spoke frankly about the sacrifices and challenges of being a female professional football player in a “She Moves Us” video conversation for Sports company PUMA: “I’ve had to challenge male standards just by being a football player. I think most people in the world see it as a male sport, but for me it’s the same. We do the same. Everything around should be the same as well. So that’s what we’re fighting for and trying to show the world”, says Norwegian National Team Player Ingrid Engen. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005655/en/ PUMA football players and athletes Nikita Parris, Ingrid Engen, Fridolina Rolfö and Sara Björk Gunnarsdottir talk “She Moves Us” ahead of Women’s Euro in England (Photo: Business Wire) English Football Star Nikita Parris was amazed by the changes that are happening with the respect for female professional athletes:” I had to challenge male stand

Kalray’s Smart Storage Acceleration Card K200-LP™, Now Integrated into Pixitmedia’s Software-Defined Storage Solution Pixstor27.6.2022 18:00:00 CEST | Press release

Kalray (Euronext Growth Paris : ALKAL) (Paris:ALKAL),a leading provider in the new generation of processors and acceleration cards specialized in Intelligent Data Processing from Cloud to Edge, is delighted to announce the first outcome of the synergetic combination of its DPU (“Data Processing Unit”) processor-based acceleration card K200-LP™ with newly acquired software-defined storage and data management solutions provider pixitmedia1, a division of Arcapix Holdings Ltd dedicated to the Media & Entertainment markets. The launch of this new joint product comes just months after Kalray's acquisition of Arcapix Holdings Ltd and the new product will be showcased at Flash Memory Summit (USA) in August. KALRAY’S ACCELERATION CARDS AND DPUs AT THE HEART OF AWARDED PIXITMEDIA’S SOFTWARE-DEFINED STORAGE AND DATA MANAGEMENT SOLUTIONS Media & Entertainment customers are amongst the most demanding in terms of data storage and data management. The award winning pixstor and ngenea products are de

CORRECTING and REPLACING Minister of Trade and Industry to Launch the Norwegian Government’s Battery Strategy at FREYR Battery’s Mo i Rana Site27.6.2022 17:59:00 CEST | Press release

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005371/en/ "Sentraltomta" inside Mo Industrial Park (Photo: Business Wire) The updated release reads: MINISTER OF TRADE AND INDUSTRY TO LAUNCH THE NORWEGIAN GOVERNMENT’S BATTERY STRATEGY AT FREYR BATTERY’S MO I RANA SITE FREYR Battery (NYSE: FREY) (“FREYR”), a developer of clean, next-generation battery cell production, is pleased to confirm that the company will welcome the Minister of Trade and Industry to launch the Norwegian Government’s National Battery Strategy at FREYR’s planned gigafactory location on June 29th in Mo i Rana, Norway. FREYR’s Chief Executive Officer, Tom Einar Jensen, remarked, “We are exceptionally proud that the Norwegian Government has selected FREYR’s planned gigafactory site in Mo i Rana to make this historic announcement. We look forward to extending a wa

Walton Global Makes Distributions of $137 Million to its Investors during Second Quarter 202227.6.2022 17:45:00 CEST | Press release

Walton Global, a real estate investment and land asset management company with US $3.6 billion under management, announced distributions made to investors will total more than US $137 Million in the second quarter 2022 as a result of strong land sales in various assets across North America. A total of US $130 Million has already been distributed to investors with more than US $7 Million expected to be made at the end of June 2022. “We have been managing our land sales pipeline diligently across all of our assets in both the U.S. and Canada,” said Kate Kaminski, chief operating officer at Walton Global. “This is the first large wave of investor distributions in 2022, but we have many other significant projects that are expected to close throughout the year.” Walton has investors that span across 73 countries around the globe. The US $137 Million distribution is an aggregate amount made up of U.S. and Canadian assets within Walton’s investment structures. U.S.-based investors received di

Landmark Study Reveals New Technology from DeBogy Molecular Significantly Reduces the Bacteria and Deadly Infection that Can Occur Following a Surgical Implant27.6.2022 15:15:00 CEST | Press release

DeBogy Molecular, Inc, a biotech startup that specializes in antimicrobial surface modification, today announced the findings of a landmark in vivo research study that affirms the effectiveness and safety of their new technology to kill the dangerous bacteria that proliferates on the surface of a medical implant following surgery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005067/en/ Wayne Gattinella CEO, DeBogy Molecular, Inc (Photo: Business Wire) Infection resulting from bacterial biofilm that forms on the surface of a medical implant represents one of the most serious complications that can follow orthopedic surgery or the implantation of a medical device. Implant related infections account for over half of the 2 million yearly healthcare-associated infections in the U.S., at a cost of over $27 billion dollars annually. A preclinical research study was conducted by Vivexia, an independent Clinical Research Orga

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom